Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?

Detalles Bibliográficos
Autores principales: Paulino, Eduardo, de Melo, Andreia Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2020
Materias:
Expert Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593230/
https://www.ncbi.nlm.nih.gov/pubmed/33078600
http://dx.doi.org/10.3802/jgo.2020.31.e95

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7593230/
https://www.ncbi.nlm.nih.gov/pubmed/33078600
http://dx.doi.org/10.3802/jgo.2020.31.e95

Ejemplares similares